Israel Biotech Fund
VC Fund
Rehovot, Israel
Israel Biotech Fund is a VC fund in Rehovot focused on Biotechnology and Health Care. Israel Biotech Fund – Building the future of Israeli BiotechIsrael Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies.Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs at or near clinical stages.Ourpartners include two top-tier international pharmaceuticals companies, institutional investors, family offices and high net worth individuals.Our key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance.We provide our portfolio companies with the necessary resources for long-term sustainable growth. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities.The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 67%
- Fund size:
- $65M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Israel Biotech Fund invests in
Stages Israel Biotech Fund invests in
Countries Israel Biotech Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $9M–$25M
- Series B
- $17M–$30M
- Series C
- $19M–$45M
Investment Focus
Industry
- Biotechnology 11 (73%)
- Health Care 7 (47%)
- Pharmaceutical 6 (40%)
- Therapeutics 4 (27%)
- Medical Device 4 (27%)
Stage
- Series A 3 (20%)
- Series B 3 (20%)
- Series C 3 (20%)
- Pre-Seed 1 (7%)
- Series F 1 (7%)
Country
- Israel 10 (67%)
- United States 2 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ido Zairi
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 1 | Find email | |
Yuval Cabilly
Co-Founder and General Partner
|
Co-Founder and General Partner | Total investments: 0 | Find email | |
David Sidransky
Co-Founder and General Partner
|
Co-Founder and General Partner | Total investments: 3 | Find email | |
Jeffrey B. Kindler
Fund Advisor
|
Fund Advisor | Total investments: 3 | Find email | |
Jonathan Fassberg
Fund Advisor
|
Fund Advisor | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ukko is a biotech firm focused on creating safe immunotherapies for quickly addressing allergies and other immune-related disorders. The company utilizes a unique technology platform that combines computational protein design with mRNA/LNP delivery to alter allergenic proteins. This approach seeks to mitigate or eliminate the risks of severeallergic reactions while eliciting a protective immune response. The Company is focused on changing the approach to prevent allergic reactions at the molecular level, striving to offer a safer and more targeted alternative to conventional desensitization techniques. This will lessen the treatment burden while meeting the critical needs of those vulnerable to severe allergic reactions to peanuts, with possibilities for extending the solution to other major allergens like milk, tree nuts, and respiratory triggers. | $45M / Series C / Jan 08, 2026 | ||
| Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. | $11M / Venture - Series Unknown / Oct 28, 2024 | ||
| Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. | $25M / Series A / Nov 30, 2022 | ||
| MediWound is a biotechnology niche-specialty company. Established in 2001, MediWound is focused on developing, manufacturing, and globally commercializing innovative products that address unmet needs in the fields of severe burns and chronic wound management.MediWound’s goal is to provide healthcare professionals and patients with its innovativeburn wound eschar removal agent, NexoBrid. NexoBrid successfully completed clinical development in hospitalized burn wounds and is approved and ready to launch in Europe. | $30M / Post-IPO Equity / Sep 22, 2022 | ||
| Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. | $16M / Venture - Series Unknown / Nov 01, 2021 | ||
| Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried. | $28.5M / Series B / May 13, 2021 | ||
| ExoProTher Medical is a biomedical startup that specializes in nano-particles cancer treatment. It offers a method of healthy p53 protein delivery into tumor cells is expected to benefit the treatment of more than 60% of human cancers. The company was founded in 2017 and is headquartered in Haifa, Israel. | Pre-Seed / Jan 01, 2021 | ||
| BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy treatments. | $27M / Series C / Dec 02, 2020 | ||
| BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy treatments. | $19M / Series C / Mar 11, 2020 | ||
| Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through acombination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis). | $30M / Series B / May 28, 2019 | ||
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Israel Biotech Fund invest in?
Israel Biotech Fund invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Israel Biotech Fund invest in?
Israel Biotech Fund typically joins rounds of $9M–$25M at Series A, $17M–$30M at Series B and $19M–$45M at Series C. These are whole funding-round sizes, not Israel Biotech Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Israel Biotech Fund took part in.
How do I contact Israel Biotech Fund?
Public channels for Israel Biotech Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Israel Biotech Fund?
The team at Israel Biotech Fund includes Ido Zairi (Co-Founder and Managing Partner), Yuval Cabilly (Co-Founder and General Partner) and David Sidransky (Co-Founder and General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
